Goldman Sachs Group Inc Graphite Bio, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$2.24 - $2.66 $11,739 - $13,941	-5,241 Reduced 15.52%	28,538 $74,000
Q3 2023 May 14, 2024	BUY	$2.18 - $2.77 $11,425 - $14,517	5,241 Added 18.36%	33,779 $83,000
Q3 2023 Nov 14, 2023	SELL	$2.18 - $2.77 $1,948 - $2,476	-894 Reduced 2.58%	33,779 $83,000
Q2 2023 May 14, 2024	BUY	$2.47 - $3.38 $53,090 - $72,649	21,494 Added 163.09%	34,673 $90,000
Q2 2023 Aug 14, 2023	BUY	$2.47 - $3.38 $53,090 - $72,649	21,494 Added 163.09%	34,673 $90,000
Q1 2023 May 14, 2024	SELL	$1.85 - $3.21 $28,532 - $49,507	-15,423 Reduced 53.92%	13,179 $32,000
Q1 2023 May 11, 2023	SELL	$1.85 - $3.21 $28,532 - $49,507	-15,423 Reduced 53.92%	13,179 $32,000
Q4 2022 May 14, 2024	SELL	$2.82 - $3.59 $629,232 - $801,043	-223,132 Reduced 88.64%	28,602 $94,000
Q4 2022 Feb 13, 2023	SELL	$2.82 - $3.59 $629,232 - $801,043	-223,132 Reduced 88.64%	28,602 $94,000
Q3 2022 May 14, 2024	SELL	$2.82 - $4.24 $469,098 - $705,311	-166,347 Reduced 39.79%	251,734 $798,000
Q3 2022 Nov 10, 2022	SELL	$2.82 - $4.24 $469,098 - $705,311	-166,347 Reduced 39.79%	251,734 $0
Q2 2022 May 14, 2024	BUY	$2.14 - $5.23 $833,622 - $2.04 Million	389,543 Added 1365.0%	418,081 $1.15 Million
Q2 2022 Aug 15, 2022	BUY	$2.14 - $5.23 $814,901 - $1.99 Million	380,795 Added 1021.28%	418,081 $1.15 Million
Q1 2022 May 16, 2022	BUY	$5.1 - $13.06 $88,714 - $227,178	17,395 Added 87.45%	37,286 $190,000
Q4 2021 Feb 14, 2022	SELL	$8.41 - $16.71 $455,973 - $905,982	-54,218 Reduced 73.16%	19,891 $247,000
Q3 2021 Nov 10, 2021	BUY	$15.81 - $28.39 $1.17 Million - $2.1 Million	74,109 New	74,109 $1.22 Million

Others Institutions Holding GRPH

# of Institutions

Shares Held

637K

Call Options Held

Put Options Held

View Full List

About Graphite Bio, Inc.

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

More about GRPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account